Parameter
| Biomarker | FGF23 | Full name | Fibroblast Growth Factor 23 | Molecular Type | protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | phosphorus metabolism regulation | ||
| Disease | Osteoporosis (OP) | Disease Subtypes | / | ||
| Organ | Bone, Kidney | Test Sample / Technology Platform | Serum (ELISA, Immunoassay by Radioimmunoassay IRMA) | ||
| Pathobiological Mechanisms | Glucocorticoids inhibit renal 1α-hydroxylase activity, leading to elevated FGF-23 levels, which promotes phosphorus excretion and results in impaired bone mineralization. | ||||
| Clinical Availability Status | Clinical trials in progress | ||||
| Notes and Dynamics | A level> 80 pg/mL indicates abnormal mineralization induced by glucocorticoids; combined with serum phosphorus testing, the diagnostic accuracy can be improved to 79%. | ||||